ClinicalTrials.gg
CompletedNCT00192491Updated Feb 8, 2008

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

A Phase 3 interventional study of FluMist and FluMist in Influenza, sponsored by MedImmune LLC. Completed. Open to participants aged 12 Months to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-02-08.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
12 Months to 15 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.

Planned enrollment
5th of 37
1,200 · median 72
Started
2000
the only one that year
Phase 3
4 of 37
none open now
Registered
6th of 37
by date
Lead sponsor
8 of 37
MedImmune LLC

Among the 37 studies testing FluMist in Influenza, Human, this one is the 5th largest by planned enrollment, is the only one that started in 2000, is one of 4 in phase 3, and was the 6th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About FluMist

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 12 Months to 15 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing FluMist in Influenza, Human, or all of them as a file.
02

Study summary

  • To compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children who receive an intranasal placebo mist concurrently with MMRIIÒ and VARIVAXÒ (Group 2 vs. Group 1).
  • To compare immune responses to the three strains of influenza (H1N1, H3N2, and B) following a two dose regimen of FluMist in children who receive the initial FluMist dose concurrently with MMRIIÒ and VARIVAXÒ and in children who receive two doses of FluMist alone (Group 2 vs. Group 3).Secondary:
  • To assess the safety and tolerability of concurrent administration of FluMist with MMRIIÒ and VARIVAXÒ.
03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
12 Months to 15 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 to 15 months of age (not reached their 16th month birthday);
  • In good health;
  • Parent/guardian available by telephone or for home visits;
  • Ability of the parent/guardian to understand and comply with the requirements of the protocol;
  • Signed by parent/guardian; and
  • Up to date with the primary series of recommended vaccines per standard clinic practice and local vaccine availability.

Exclusion criteria

Exclusion Criteria:

  • Previous known measles, mumps, rubella or varicella disease;
  • Previous vaccination against measles, mumps, rubella or varicella disease;
  • to egg or egg protein;
  • Signs or symptoms of any or immune deficiency disease or ongoing immunosuppressive therapy; or an immunosuppressed individual living in the same household;
  • Acute febrile (>100.0oF [37.8°C] oral) illness or upper respiratory illness within the 72 hours prior to enrollment;
  • Use of aspirin (acetylsalicylic acid) or aspirin-containing products in the month prior to enrollment, or expected use of aspirin while enrolled in this study;
  • Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;
  • Administration of any within one month prior to enrollment through 30 days after Visit 3;
  • Administration of any inactivated vaccine within two weeks prior to enrollment through 30 days after Visit 3;
  • Participation in another trial within one month prior to enrollment or expected enrollment in another investigational trial during this study;
  • Receipt of any blood product within three months prior to vaccination or expected receipt within the study duration; and
  • Any condition which, in the opinion of the investigator, would interfere with the interpretation or evaluation of the vaccines.
  • History of two or more episodes of medically attended wheezing illness by parent/guardian report.
  • History of medically attended wheezing illness or bronchodilator medication use within four weeks of enrollment by parent/guardian report.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
1,200 participants (estimated)

Study arms

  • Active comparator
    2

    FluMist

    Biological: FluMist

  • Placebo comparator
    3

    Placebo

    Other: Placebo

  • Active comparator
    1

    FluMist with other solution

    Biological: FluMist

Interventions

  • BiologicalFluMist

    Nasal Sprayer of one dosage of FluMist and other experimental

  • BiologicalFluMist

    Nasal sprayer of FluMist

  • OtherPlacebo

    Nasal Sprayer of Placebo

06

What researchers measure

Primary outcomes

  1. compare immune responses to measles, mumps, rubella, and varicella antigens following vaccination in children who receive FluMist concurrently with MMRIIÒ and VARIVAXÒ and in children

    Time frame: Day 42

Secondary outcomes

  1. Compare immune responses to the three strains of influenza (H1N1, H3N2, and B) following a two dose regimen of FluMist in children who receive the initial FluMist

    Time frame: Day 42

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics. 2008 Mar;121(3):508-16. doi: 10.1542/peds.2007-1064. PubMed 18310199 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2000, a primary completion of Sep 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Dec 2000
Primary completionEst.
Sep 2003
CompletionActual
Dec 2003
Last update
Feb 8, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00192491
Lead sponsor
MedImmune LLC
First posted
Sep 19, 2005
Start date
Dec 2000
Primary completion
Sep 2003 (estimated)
Completion
Dec 2003
Last update
Feb 8, 2008

Study contacts

Robert Walker, M.D.
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion